If you’re looking for an effective and long-lasting treatment for moderate to severe plaque psoriasis, you’ve likely heard of Ilumya. But who makes it? Ilumya is manufactured by Sun Pharmaceutical Industries, a pharmaceutical company that has been in operation for over 25 years. Sun Pharma is a global leader in the development of innovative medicines, and their commitment to research and development has resulted in many groundbreaking treatments. With Ilumya, Sun Pharma has created a therapy that provides fast-acting and long-lasting relief for those living with moderate to severe plaque psoriasis. In this article, we’ll explore more about Sun Pharma and the development of Ilumya.
Ilumya is a prescription medicine used to treat adults with moderate to severe plaque psoriasis. It is manufactured by Sun Pharmaceutical Industries Ltd., an Indian multinational pharmaceutical company that is one of the largest companies in India. The company is also the world’s fifth largest specialty generic pharmaceutical company.
Who Makes Ilumya?
Ilumya (tildrakizumab-asmn) is a prescription medication used to treat adults with moderate-to-severe plaque psoriasis. It is manufactured by Sun Pharmaceuticals Industries Ltd., an Indian multinational pharmaceuticals company.
Background and History
Sun Pharmaceuticals Industries Ltd. is one of the world’s leading pharmaceutical companies. It was founded in 1983 in India and has since become one of the world’s most respected generic drug manufacturers. Sun Pharma is also involved in research and development, manufacturing, and marketing of a broad range of branded and generic pharmaceuticals products.
How Ilumya is Made
Ilumya is a monoclonal antibody that works by blocking the activity of the interleukin-23 (IL-23) protein. This protein is responsible for the inflammation and plaque build-up associated with plaque psoriasis. Ilumya is manufactured in Sun Pharma’s facility in Gujarat, India, under the strictest quality control measures.
Clinical Research
Sun Pharma has conducted extensive clinical trials of Ilumya. The results of the trials showed that Ilumya was effective in reducing the signs and symptoms of plaque psoriasis, including skin lesions, itching, scaling, redness, and thickness of the skin. The trials also showed that Ilumya had a good safety profile, with no serious adverse events reported.
Availability
Ilumya is approved for use in adults with moderate-to-severe plaque psoriasis in the United States, Europe, Australia, Canada, and several other countries. It is available in the form of a prefilled syringe and is administered by a healthcare professional.
Conclusion
Ilumya is an effective treatment option for adults with moderate-to-severe plaque psoriasis. It is manufactured by Sun Pharmaceuticals Industries Ltd., an Indian multinational pharmaceuticals company, and is available in several countries around the world. Ilumya has a good safety profile, with no serious adverse events reported in clinical trials.
Related FAQ
What is Ilumya?
Ilumya is a prescription topical medication indicated for patients 18 years and older with moderate to severe plaque psoriasis. Ilumya contains the active ingredient tildrakizumab, a human interleukin-23 (IL-23) antagonist, which works to reduce inflammation associated with psoriasis.
Who Makes Ilumya?
Ilumya is manufactured and marketed by Sun Pharmaceutical Industries Ltd. Sun Pharmaceutical Industries Ltd. is a leading global specialty generic pharmaceutical and active pharmaceutical ingredients (API) manufacturer. Sun has strong presence in over 100 countries across the world, with significant presence in the US, India, and Europe.
What is Tildrakizumab?
Tildrakizumab is a human interleukin-23 (IL-23) antagonist and the active ingredient in Ilumya. IL-23 is a protein involved in inflammation and is believed to play a role in the development of plaque psoriasis. Tildrakizumab works by blocking IL-23, thereby reducing inflammation and improving psoriasis symptoms.
What are the Benefits of Ilumya?
The benefits of Ilumya include improved skin clarity and reduced redness and itching associated with psoriasis. In clinical trials, Ilumya demonstrated clinically relevant improvements in skin clarity and reduction in redness and itching at 12 weeks.
How is Ilumya Administered?
Ilumya is a topical medication that is applied to the skin. Ilumya is administered as a single-dose injection, which is administered on the skin of the affected area by a healthcare provider.
What are the Potential Side Effects of Ilumya?
The potential side effects of Ilumya include redness, itching, burning, stinging, swelling, or a rash at the injection site. Other potential side effects of Ilumya include upper respiratory tract infections, headache, and joint pain. If you experience any of these side effects, contact your healthcare provider.
Ilumya is a groundbreaking treatment for adults with moderate to severe plaque psoriasis, created by Sun Pharma, one of the world’s largest and most innovative pharmaceutical companies. It is designed to reduce the size and severity of psoriasis plaques, allowing users to experience clear, healthy skin. With its innovative formulation, Ilumya can provide long-term relief from moderate to severe plaque psoriasis and its associated symptoms, allowing users to enjoy a life free from the burden of psoriasis. Sun Pharma’s Ilumya is a revolutionary way to experience clear, healthy skin – now and in the future.